Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 7/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3117348 | 0.88 | SMN1; SMN2 (0.58) | TRPV1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL3109283 | 0.87 | PTPN1 (0.51) | NPC1RAB9AKMT2ASMN1; SMN2MAPT | |
| SCHEMBL3120279 | 0.85 | RAB9A (0.57) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3117290 | 0.85 | TRPV1 (0.47) | TRPV1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL3116564 | 0.83 | PTPN1 (0.50) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3116048 | 0.82 | P4HTM (0.54) | LMNANPC1RAB9AMEN1KMT2A | |
| SCHEMBL3107074 | 0.81 | CYP11B1 (0.46) | NPC1RAB9AMEN1KMT2AMAPT | |
| SCHEMBL13248873 | 0.80 | NPY5R (0.49) | MEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL3117708 | 0.79 | KCNQ3 (0.56) | LMNANPC1RAB9AMEN1KMT2A | |
| SCHEMBL14609473 | 0.77 | ULK1 (0.47) | KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179161-A1 | PYRAZOLINE DERIVATIVES FOR THE TREATMENT OF TURBERCULOSIS | ASTRAZENECA AB (SE) | 2010-07-15 | — | — | US | disclosed |
| US-20100179161-A1 | PYRAZOLINE DERIVATIVES FOR THE TREATMENT OF TURBERCULOSIS | ASTRAZENECA AB (SE) | 2010-07-15 | — | — | US | disclosed |
| US-20100179161-A1 | PYRAZOLINE DERIVATIVES FOR THE TREATMENT OF TURBERCULOSIS | ASTRAZENECA AB (SE) | 2010-07-15 | — | — | US | disclosed |
| CN-101291923-A | Pyrazolone derivatives for the treatment of tuberculosis | ASTRAZENECA AB (SE) | 2008-10-22 | — | — | CN | disclosed |
| EP-1919890-A1 | PYRAZOLONE DERIVATIVES FOR THE TREATMENT OF TUBERCULOSIS | AstraZeneca AB (SE) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007020426-A1 | PYRAZOLONE DERIVATIVES FOR THE TREATMENT OF TUBERCULOSIS | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179161-A1 | PYRAZOLINE DERIVATIVES FOR THE TREATMENT OF TURBERCULOSIS | TREH, TYMP, EPX | LMNA 1808/4885TRPV1 2392/4885NPC1 2396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.